161 related articles for article (PubMed ID: 26717875)
1. β-catenin is regulated by USP9x and mediates resistance to TRAIL-induced apoptosis in breast cancer.
Ouyang W; Zhang S; Yang B; Yang C; Zhang J; Zhou F; Xie C
Oncol Rep; 2016 Feb; 35(2):717-24. PubMed ID: 26717875
[TBL] [Abstract][Full Text] [Related]
2. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Liu X; Yue P; Khuri FR; Sun SY
Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375
[TBL] [Abstract][Full Text] [Related]
3. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.
Sanlioglu AD; Dirice E; Aydin C; Erin N; Koksoy S; Sanlioglu S
BMC Cancer; 2005 May; 5():54. PubMed ID: 15916713
[TBL] [Abstract][Full Text] [Related]
4. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer.
De Toni EN; Thieme SE; Herbst A; Behrens A; Stieber P; Jung A; Blum H; Göke B; Kolligs FT
Clin Cancer Res; 2008 Aug; 14(15):4713-8. PubMed ID: 18676739
[TBL] [Abstract][Full Text] [Related]
5. USP9X-mediated deubiquitination of B-cell CLL/lymphoma 9 potentiates Wnt signaling and promotes breast carcinogenesis.
Shang Z; Zhao J; Zhang Q; Cao C; Tian S; Zhang K; Liu L; Shi L; Yu N; Yang S
J Biol Chem; 2019 Jun; 294(25):9844-9857. PubMed ID: 31073027
[TBL] [Abstract][Full Text] [Related]
6. ELF3 plays an important role in defining TRAIL sensitivity in breast cancer by modulating the expression of decoy receptor 2 (DCR2).
Ghosal N; Tapadar P; Biswas D; Pal R
Mol Biol Rep; 2024 May; 51(1):671. PubMed ID: 38787503
[TBL] [Abstract][Full Text] [Related]
7. Deubiquitinase USP9X deubiquitinates β-catenin and promotes high grade glioma cell growth.
Yang B; Zhang S; Wang Z; Yang C; Ouyang W; Zhou F; Zhou Y; Xie C
Oncotarget; 2016 Nov; 7(48):79515-79525. PubMed ID: 27783990
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.
Shivapurkar N; Toyooka S; Toyooka KO; Reddy J; Miyajima K; Suzuki M; Shigematsu H; Takahashi T; Parikh G; Pass HI; Chaudhary PM; Gazdar AF
Int J Cancer; 2004 May; 109(5):786-92. PubMed ID: 14999791
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
10. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
[TBL] [Abstract][Full Text] [Related]
11. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
12. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
[TBL] [Abstract][Full Text] [Related]
13. Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells.
Senthivinayagam S; Mishra P; Paramasivam SK; Yallapragada S; Chatterjee M; Wong L; Rana A; Rana B
J Biol Chem; 2009 May; 284(20):13577-13588. PubMed ID: 19289465
[TBL] [Abstract][Full Text] [Related]
14. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1alpha-mediated mechanism.
Pei GT; Wu CW; Lin WW
Biochem Biophys Res Commun; 2010 Jan; 391(2):1274-9. PubMed ID: 20018172
[TBL] [Abstract][Full Text] [Related]
16. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
17. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
19. Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.
Jalving M; Heijink DM; Koornstra JJ; Boersma-van Ek W; Zwart N; Wesseling J; Sluiter WJ; de Vries EG; Kleibeuker JH; de Jong S
Carcinogenesis; 2014 May; 35(5):1092-9. PubMed ID: 24379239
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of USP9X reverses cisplatin resistance by decreasing β-catenin expression in nasopharyngeal carcinoma cells.
Lu WX; Gan GS; Yang B
Neoplasma; 2021 Jul; 68(4):810-822. PubMed ID: 34097426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
